Trevor Marshall

Trevor G. Marshall (b. 1948, Adelaide, South Australia), is a biomedical researcher. He developed what is known as the "Marshall Protocol" as a possible treatment of a class of chronic diseases, which he argues are caused by L-form or cell wall deficient bacteria. Waterhouse, in a 2007 "Townsend Letter" article, stated the protocol has been used successfully to treat many chronic conditions, including chronic Lyme disease, Sarcoidosis, Fibromyalgia, and rheumatoid arthritis.Waterhouse, JC. (2007). The Marshall Protocol for Lyme disease and other chronic inflammatory conditions, Part One: overview and implementation. Townsend Letter for Doctors and Patients. Retrieved December 5, 2007 from http://findarticles.com/p/articles/mi_m0ISW/is_285/ai_n19170371] It involves the use of low-dose antibiotics, an angiotensin II receptor antagonist (being used as a VDR agonist), [ Marshall, TG. "Bacterial Capnine Blocks Transcription of Human Antimicrobial Peptides." Metagenomics 2007. San Diego, CA. 2007 July 11-13. Retrieved 2007-12-07 from http://metagenomics.calit2.net/files/Metagenomics2007Program_lowres.pdf.] and avoidance of sources of Vitamin D such as sunlight, as a possible treatment of a class of chronic diseases.

The protocol's critics state that the efficacy to treat autoimmune diseases has not been confirmed with peer-reviewed data and results by the medical community.

Background and Early Work

Trevor Marshall received his PhD in Electrical Engineering from the University of Western Australia in 1984. [Marshall, T. G. (1984). [http://catalogue.library.uwa.edu.au/search?/XTrevor+Marshall&searchscope=1&SORT=AZ/XTrevor+Marshall&searchscope=1&SORT=AZ&extended=0&SUBKEY=Trevor%20Marshall/1%2C7%2C7%2CB/frameset&FF=XTrevor+Marshall&searchscope=1&SORT=AZ&1%2C1%2C, Modelling and simulation in diabetes care] Unpublished doctoral dissertation, University of Western Australia.] He also possesses an undergraduate and a masters (1978) degree in Electrical Engineering. []

Criticism of the Marshall Protocol

The Marshall Protocol's efficacy to treat autoimmune diseases has not been validated by the medical community. Rosen and Bagwell, in their 2007 review of treatments for sarcoidosis, argue that the Marshalls' 2003 paper, "Antibiotics in sarcoidosis—reflections of the first year" has "serious deficiencies", and the data has not been peer-reviewed nor the results quantified.Badgwell, C & Rosen, T. (2007). Cutaneous sarcoidosis therapy updated. Journal of the American Academy of Dermatology, 56(1): 69-83. Retrieved 2007-12-05 from http://dx.doi.org/10.1016/j.jaad.2006.06.019 PMID 17190623]

References

External links

* [http://www.marshallprotocol.com Marshall Protocol]
* [http://www.sarcinfo.com SarcInfo]